Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilumya in moderate-to-severe psoriasis and epigenetic aging
NCT05110313Phase 4Completed
- Start
- Apr 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of tildrakizumab in psoriasis. Started Apr 2022; status: completed.
02
Drugs
tildrakizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05110313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110313.